Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/hed.27463
Keywords
antigen-specific T cell responses; HPV; neoadjuvant chemotherapy; oropharyngeal cancer; pathologic response
Categories
Ask authors/readers for more resources
In this study, we found that neoadjuvant chemotherapy can enhance HPV-specific T cell responses in patients with newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma, leading to a high recurrence-free survival rate. Furthermore, we observed an increase in HPV16-specific lymphocyte responses after chemotherapy in some patients. However, lack of an increase in response following chemotherapy was associated with a higher risk of relapse.
BackgroundTreatment of patients with newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) with neoadjuvant chemotherapy (NAC) results in a high rate of 5-year recurrence free survival with few patients requiring adjuvant treatment. We hypothesized that NAC enhances primary tumor HPV-specific T cell responses. MethodsHPV-specific responses in tumor infiltrating lymphocytes (TILs) before and after NAC were determined using autologous co-culture assays. ResultsGreater HPV16-specific TIL responses, sometimes polyclonal, were observed after NAC compared to before in 8 of 10 patients (80%) with PCR-verified HPV16-positive tumors. A significant association was observed between net-negative change in HPV-specific TIL response and disease relapse (p = 0.04, Mann-Whitney test), whereas pathologic complete response at time of surgery did not correlate with recurrence. ConclusionsNAC induces HPV-specific tumor T cell responses in patients with newly diagnosed HPV-associated OPSCC; whereas lack of an increase following NAC may associate with risk of relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available